Response to Comment on Chen et al. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. Diabetes Care 2020;43:1399–1407
Yuchen Chen, Dong Yang, Chen Yang, Ling Zheng, Kun Huang
Abstract
We appreciate the comments by Cariou et al. (1) regarding our investigation (2) and their intermediate analysis of the CORONADO (CORONAvirus SARS-CoV-2 and Diabetes Outcomes) study (3), and we thank them for sharing important points. Currently, joint early efforts reveal that patients with diabetes and coronavirus disease 2019 (COVID-19) undergo more severe inflammation and worse prognosis, and no evidence suggests the need for stopping any glucose-lowering therapy (2,3), since high blood glucose during hospitalization has also been suggested as a risk factor for poor outcomes in patients with diabetes with COVID-19 (4). We acknowledge Cariou et al. for sharing additional independent predictive factors associating with early death on day …